Non-Adherence To Chronic Leukemia Drugs Tied To High Copays In Study
Executive Summary
Burdensome cost sharing is linked with a 70% increase in the risk of discontinuing Gleevec, Tasigna or Sprycel among patients with chronic myeloid leukemia and a 42% increased risk of inadequate adherence, according to a study published in the Journal of Clinical Oncology.